Syndax Pharmaceuticals Inc., of Waltham, Mass., said it agreed to sell about 2 million shares of common stock to Biotechnology Value Fund LP and certain of its affiliates in a registered direct offering for gross proceeds of about $25 million based on the offering price of $12.37 per share, representing the closing price of the company's shares on Oct. 13.